Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page

NTRK gene fusions are oncogenic drivers and the resultant TRK fusion protein is a treatment target across many tumour types. The following section describes the various mechanisms of TRK activation in cancer, what NTRK gene fusions are, including how they are formed and their resulting activity, and the epidemiology of NTRK gene fusions.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings